| Assessment Status | Rapid Review Complete |
| HTA ID | 23053 |
| Drug | Loncastuximab tesirine |
| Brand | Zynlonta® |
| Indication | Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 17/08/2023 |
| Rapid review completed | 01/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of loncastuximab tesirine compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
